General MedicationsORALGeneric
NALOXEGOL
NALOXEGOL
Standard Dose
12.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary
Approval overview NALOXEGOL is listed in Drugs@FDA under application 212625 (ANDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient NALOXEGOL Form and strength TABLET;ORAL - 12.5MG Sponsor MSN LABS PVT LTD Submission history Latest submission status date: 2021-02-24 00:00:00.
Structured Monograph
Clinical summary
Approval overview NALOXEGOL is listed in Drugs@FDA under application 212625 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient NALOXEGOL Form and strength TABLET;ORAL - 12.5MG Sponsor MSN LABS PVT LTD Submission history Latest submission status date: 2021-02-24 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.